Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vireo GrowthVREOF -3.52%51 EV-to-EBITDA is 19.25 as of Sep. 21, 2026, which is 253% above its 10-year median of 5.46. GuruFocus rates VREOF with a GF Score™ of 51/100 and a GF Value™ of $12.64 (Fairly Valued). The stock has 6 warning signs investors should review. Among 746 Drug Manufacturers companies, Vireo Growth ranks worse than 66.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vireo Growth's enterprise value is $976.5 Mil.
Vireo Growth's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $50.7 Mil. Therefore, Vireo Growth's EV-to-EBITDA for today is 19.25.
The historical rank and industry rank for Vireo Growth's EV-to-EBITDA or its related term are showing as below:
VREOF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -622.47 Med: 5.46 Max: 6051.4
Current: 19.25
During the past 13 years, the highest EV-to-EBITDA of Vireo Growth was 6051.40. The lowest was -622.47. And the median was 5.46.
VREOF's EV-to-EBITDA is ranked worse than 66.22% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.395
vs VREOF: 19.25
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vireo Growth's PE Ratio (TTM) for today is calculated as:
Vireo Growth's share price for today is $11.50.
Vireo Growth's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.977.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vireo Growth's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vireo Growth's EV-to-EBITDA falls into.
Vireo Growth's current Enterprise Value is $976.5 Mil.
Vireo Growth's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $50.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (VREOF) has a EV-to-EBITDA of 19.25 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vireo Growth. This is 253% above median its historical median of 5.46. According to the industry distribution chart, Vireo Growth ranks #494 out of 746 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Vireo Growth's EV-to-EBITDA too high?
Vireo Growth's current EV-to-EBITDA of 19.25 is 253% above median its 10-year median of 5.46. The Drug Manufacturers industry median EV-to-EBITDA is 12.40. Vireo Growth's value of 19.25 is 55.3% above this industry median. Based on the distribution chart, Vireo Growth ranks #494 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vireo Growth has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #494 out of 746 companies for EV-to-EBITDA. This places Vireo Growth in the lower half of its industry. The industry median EV-to-EBITDA is 12.40. Vireo Growth's value of 19.25 is 55.3% above this benchmark. While the company's 10-year median is 5.46 vs. the industry median of 12.40, Vireo Growth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.40, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current EV-to-EBITDA of 19.25 is 55.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vireo Growth. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current EV-to-EBITDA is 19.25, which is 253% above median its own 10-year median of 5.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $12.64, compared to a current price of $11.50 — trading 9% below its estimated fair value. The current EV-to-EBITDA is 19.25, which is 253% above median its 10-year median of 5.46 and 55.3% above the Drug Manufacturers industry median of 12.40. Vireo Growth's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vireo Growth (VREOF), the current EV-to-EBITDA is 19.25 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be undervalued.
The current stock price of $11.50 is trading 9% below its estimated GF Value™ of $12.64.
GuruFocus considers Vireo Growth to be Fairly Valued.
Key valuation signals for VREOF:
EV-to-EBITDA: 19.25 (253% above median its 10-year median of 5.46)
GF Value™: $12.64 vs. price of $11.50 (9% below fair value)
Industry Position: 55.3% above the Drug Manufacturers median (#494 of 746)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
51GF Score
Get the complete analysis for VREOF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
